Prism Medico & Pharmacy recently reported its financial results for the quarter ended September 30, revealing a mixed performance with a quarterly loss despite a profitable half-year. The company also addressed a filing error by re-uploading its complete financial statements to stock exchanges.

Financial Performance

For the quarter ended September 30, Prism Medico reported:

The company's revenue saw a significant decline of 68.75% compared to the previous quarter. This sharp decrease in revenue contributed to the quarterly loss of ₹0.10 crore, contrasting with a profit of ₹0.70 crore in the preceding quarter.

Half-Year Performance

Despite the weak quarterly results, Prism Medico's half-year performance shows some resilience:

• Half-year profit: ₹57.25 lakh
• This positive half-year result was primarily driven by the strong performance in the first quarter of the fiscal year.

Operating Efficiency

The company's operating profit margin (OPM) for the quarter stood at -20.00%, a substantial decline from 40.88% in the previous quarter. This negative margin indicates challenges in maintaining profitability amid declining revenues.

Filing Correction

Prism Medico addressed an inadvertent omission in its original financial statement filing to stock exchanges. The company re-uploaded the complete set of financial statements, including the Statement of Assets and Liabilities and Cash Flow Statement, which were initially missing from the PDF file. This correction ensures compliance with regulatory requirements and provides investors with comprehensive financial information.

Outlook

While the company faces short-term challenges as evidenced by the quarterly loss and revenue decline, the positive half-year profit suggests some underlying strength. Management's strategies to address the revenue decline and improve operational efficiency may be crucial for the company's performance in the remainder of the fiscal year.

Prism Medico & Pharmacy Limited has reported a significant turnaround in its financial performance for the first quarter. The company's Board of Directors approved the unaudited standalone financial results, showcasing substantial growth in revenue and profitability.

Financial Highlights

• Revenue Surge: The company's revenue from operations skyrocketed to ₹158.87 lakhs, marking a remarkable increase from ₹7.28 lakhs in the previous quarter and ₹6.27 lakhs in the corresponding quarter last year.

• Profit Boost: Net profit for the quarter reached ₹65.73 lakhs, compared to ₹4.15 lakhs in the previous quarter and a loss of ₹9.00 lakhs in the year-ago period.

• Earnings Per Share: The company's earnings per share improved to ₹0.01 from ₹0.00 in the previous quarter.

Quarterly Performance Overview

Key Observations

• Cost Management: Despite the significant increase in revenue, the company managed to keep its expenses under control. Total expenses for the quarter were ₹93.84 lakhs, with the cost of materials consumed being the largest component at ₹85.75 lakhs.

• Operational Efficiency: The company demonstrated improved operational efficiency, turning a loss-making position from the previous year into a profitable one.

• Capital Structure: The paid-up equity share capital remained stable at ₹606.34 lakhs.

Management Commentary

The financial results were reviewed by auditors Garg Mendiratta & Associates and approved by the Board. The company's management expressed satisfaction with the strong quarterly performance, highlighting the significant improvement in both top-line and bottom-line figures.

Regulatory Compliance

In compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Prism Medico & Pharmacy Limited has submitted these results to the stock exchanges. The limited review report by the auditors stated that nothing has come to their attention that causes them to believe that the financial results do not present a true and fair view in accordance with applicable accounting standards.

Investors and stakeholders will be keenly watching to see if Prism Medico & Pharmacy Limited can maintain this growth trajectory in the coming quarters.